Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY 4.0Advanced Pharmaceutical Bulletin

Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives

7 affiliations
  1. 1Department of Pharmacology, Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai Tamil Nadu, India
  2. 2Department of Community Medicine, Apollo Institute of Medical Sciences And Research Chittoor, India
  3. 3Department of Physiotherapy, Apollo College of Physiotherapy, the Apollo Knowledge Centre, Murukambattu, Chittoor 517127, India
  4. 4Division of Allied Health Sciences, School of Health Sciences, the Apollo University, Murukambattu, Chittoor, India
  5. 5Saveetha College of Physiotherapy, Saveetha Institute of Medical and Technical Sciences, Chennai, India
  6. 6Department of Pharmaceutical Chemistry, Apollo Institute of Pharmaceutical Sciences, The Apollo University, The Apollo Knowledge City Saketa, Chittoor, India
  7. 7School of Social Sciences, The Apollo University, Chittoor, India

Abstract

Purpose:: Epigenetic dysregulation is increasingly recognized as a fundamental driver of cell cycle checkpoint failure in colorectal cancer. Beyond genetic mutations, epigenetic mechanisms provide a dynamic and potentially reversible layer of control over cyclin-dependent kinase activity and tumor progression. This mechanistic critical review examines how epigenetic alterations reshape cell cycle regulation in colorectal cancer and evaluates their translational relevance.

Methods:: This review adopts a critical mechanistic approach, integrating and interpreting evidence from experimental, translational and clinical studies addressing epigenetic regulation of cell cycle control in colorectal cancer. Rather than following a systematic review framework, the literature was evaluated conceptually to identify dominant mechanisms, areas of convergence and unresolved controversies.

Results:: Evidence indicates that aberrant DNA methylation, histone modifications and chromatin remodeling converge to repress key cyclin-dependent kinase inhibitors including p16INK4a, p21Cip1 and p27Kip1. These epigenetic alterations sustain cyclin–CDK activity thereby promote bypass of G1/S checkpoint control and facilitate uncontrolled proliferation. Importantly, epigenetic heterogeneity across colorectal tumors contributes to variable therapeutic responses and resistance to both conventional and epigenetic-targeted therapies.

Conclusion:: Epigenetic control of cell cycle checkpoints represents a central and therapeutically exploitable mechanism in colorectal cancer. A mechanistic understanding of these regulatory networks highlights opportunities for rational combination strategies and precision-based interventions while underscoring current knowledge gaps that warrant further investigation.

Related

  1. Epigenetic regulation of immune checkpoint signaling by microbial metabolites: mechanisms, therapeutic potential, and future perspectives
    Asiya Nazir, Rafia Nazir, Sarika Sharma +2
    Frontiers in immunologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCCrossref
  2. Crosstalk between PI3K/AKT signaling and epigenetic regulation in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities
    Zhibo Zhang, Jie Liu, Guofeng Lei +1
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCPMC
  3. Epigenetic Mechanisms in Neurodegenerative Diseases: From Genetic Regulation to Therapeutic Potential
    Xiaoman Lv, Mincong Huang, Wenjuan Long +8
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefEurope PMC
  4. Epigenetic Regulation of Pyroptosis in Kidney Disease: From Molecular Mechanisms to Therapeutic Potential
    Daoyu Sheng, Shanshan Han, Wenya Shang +1
    Journal of Inflammation ResearchPeer-reviewedCC BY-NC 4.0Full textMolecular biology & gene regulationPMC
  5. Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.
    Shaocun Zhang, Yu Wang, Xin Min +2
    Signal transduction and targeted therapyPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMC
BibTeX
@article{srinivasa2026epigenetic,
  title = {{Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives}},
  author = {Srinivasa B and Devika P Jeeragyal and Kiran Velukuri and Amarnath Reganti and Vaheedha S and Vinodhkumar Ramalingam and Rajasekar Sreerama and Neelima Grandhe and Praveen Hoogar},
  journal = {Advanced Pharmaceutical Bulletin},
  year = {2026},
  month = may,
  doi = {10.34172/apb.47190},
  url = {https://doi.org/10.34172/apb.47190},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives
AU  - Srinivasa B
AU  - Devika P Jeeragyal
AU  - Kiran Velukuri
AU  - Amarnath Reganti
AU  - Vaheedha S
AU  - Vinodhkumar Ramalingam
AU  - Rajasekar Sreerama
AU  - Neelima Grandhe
AU  - Praveen Hoogar
PY  - 2026
DA  - 2026/05/23
JO  - Advanced Pharmaceutical Bulletin
DO  - 10.34172/apb.47190
UR  - https://doi.org/10.34172/apb.47190
AB  - Purpose:: Epigenetic dysregulation is increasingly recognized as a fundamental driver of cell cycle checkpoint failure in colorectal cancer. Beyond genetic mutations, epigenetic mechanisms provide a dynamic and potentially reversible layer of control over cyclin-dependent kinase activity and tumor progression. This mechanistic critical review examines how epigenetic alterations reshape cell cycle regulation in colorectal cancer and evaluates their translational relevance.  Methods:: This review adopts a critical mechanistic approach, integrating and interpreting evidence from experimental, translational and clinical studies addressing epigenetic regulation of cell cycle control in colorectal cancer. Rather than following a systematic review framework, the literature was evaluated conceptually to identify dominant mechanisms, areas of convergence and unresolved controversies.  Results:: Evidence indicates that aberrant DNA methylation, histone modifications and chromatin remodeling converge to repress key cyclin-dependent kinase inhibitors including p16INK4a, p21Cip1 and p27Kip1. These epigenetic alterations sustain cyclin–CDK activity thereby promote bypass of G1/S checkpoint control and facilitate uncontrolled proliferation. Importantly, epigenetic heterogeneity across colorectal tumors contributes to variable therapeutic responses and resistance to both conventional and epigenetic-targeted therapies.  Conclusion:: Epigenetic control of cell cycle checkpoints represents a central and therapeutically exploitable mechanism in colorectal cancer. A mechanistic understanding of these regulatory networks highlights opportunities for rational combination strategies and precision-based interventions while underscoring current knowledge gaps that warrant further investigation.
SN  - 2228-5881
SN  - 2251-7308
ER  -